GlassScriptPhysician profile
Albert Thomas Quiery
NPI 1164487120
$4,005.44
in general payments reported to CMS, 2019-2025
58 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.24 · 2022: $38.21 · 2023: $989 · 2024: $1,535 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,852 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,851.99 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $497.77 | 2019-2025 | |
| Genentech USA, INC. | $241.00 | 2023-2025 | Polivy, Venclexta, Lunsumio |
| Merck Sharp & Dohme LLC | $213.62 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $191.10 | 2023-2025 | Reblozyl, Pomalyst, Pomalyst |
| Incyte Corporation | $190.56 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $172.46 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Daiichi Sankyo INC. | $136.20 | 2023-2025 | Injectafer, Enhertu, Datroway |
| Pfizer INC. | $127.52 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $123.71 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astellas Pharma US INC | $114.42 | 2023-2025 | Padcev, Cresemba, Xospata |
| Genzyme Corporation | $108.95 | 2023-2024 | |
| Lilly USA, LLC | $107.96 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $96.05 | 2023-2025 | Enhertu, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $94.40 | 2023-2025 | Ninlaro |
| Alexion Pharmaceuticals, INC. | $91.96 | 2023-2024 | Ultomiris |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Quiery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.